BrainsWay and the private options: strategic investments buy growth paths but reduce excess cash
BrainsWay opened 2026 with a profitable quarter, but $8.5 million of financial-asset purchases made the cash test more important. The Neurolief, Axis and BrainStim deals buy strategic growth paths, but they are not yet visible operating revenue engines.
BrainsWay entered 2026 with a quarter that shows the existing business can already be profitable, but this follow-up isolates a different issue: the company is starting to turn part of its excess cash into private growth options that are still hard to measure through revenue. First-quarter revenue was $15.5 million, net income was $2.3 million, and adjusted EBITDA was $2.8 million, so this is not a company buying time from a weak position. Still, cash and cash equivalents fell from $67.7 million at the end of 2025 to $58.6 million at the end of March, mainly because the company purchased $8.5 million of financial assets. That turns the Neurolief, Axis and BrainStim investments from a broad strategic story into a real capital-allocation test: will this capital buy access to markets and clinics that flows back into results, or remain private assets that need more milestones before their cash value is clear. The current read is mixed but leans constructive: the cash balance is still comfortable and the core business is profitable, but excess cash is less excessive than it looks if the analysis stops at the income statement. The next proof will not come from signing the investments themselves, but from Neurolief revenue, MSO investment maturity, and the ability of the existing business to fund additional investments without continued cash erosion at a similar pace.
Cash Fell Because Investments Moved Ahead Of Contribution
The first quarter gives BrainsWay a solid starting point: the core business generated $1.2 million of operating cash flow after $2.3 million of net income. This is not only an accounting-profit picture, but it is also not a quarter where all profit stayed in cash. A $3.5 million increase in trade receivables absorbed part of the improvement, and operating cash flow was below net income.
The all-in cash picture after the quarter's actual cash uses is sharper. The $8.5 million purchase of financial assets was the dominant cash use, far above operating cash flow. Together with purchases of property, equipment and system components, commission assets, repayments of development grants and leases, cash and cash equivalents fell by $9.1 million. In other words, the existing business funded only a small part of the quarter's private-investment push.
The balance sheet shows where the cash went: non-current financial assets rose from $14.7 million at the end of 2025 to $23.2 million at the end of March 2026. This is not a small line-item shift, but a rising weight of private investments inside the balance sheet. Until those investments turn into revenue, RPO or cash flow, they buy growth optionality rather than improve current earnings quality.
Deal Terms Reduce Risk But Do Not Make The Assets Liquid
Neurolief is the larger and more important deal. BrainsWay first invested $5 million through a convertible loan at a $30 million pre-money valuation, potentially converting into about 12.9% of Neurolief on a fully diluted basis. A second $6 million investment was made in March 2026 after a regulatory milestone, at a $45 million pre-money valuation. The third investment, up to another $5 million, now depends on a clearer commercial milestone: $10 million of trailing 12-month revenue based on US GAAP reviewed financials.
That transition matters. The milestone already triggered was FDA approval for the ProlivRx system for treatment-resistant depression as an adjunctive therapy that can be administered at home or in a clinic. From here, the next proof point is not only regulatory. If Neurolief does not show enough revenue to trigger the third investment, the strategic option remains mostly on paper even after an important product milestone.
The Neurolief call option adds upside, but its structure also ties value to revenue. The exercise price is based on the greater of minimum value thresholds of $65 million in the initial period and $90 million in the final period, or 4.5 times trailing six-month annualized revenue, adjusted for debt and cash. This protects the sellers if revenue develops, and it does not give BrainsWay a cheap acquisition right without business proof.
Axis and BrainStim are smaller, but they show the same pattern. Axis began as a $2.3 million investment for about 29.5% on a fully diluted basis, followed by another $1 million investment after a revenue milestone was met. BrainStim received an initial $1 million investment, with potential additional milestone-based investments of up to $1.5 million. In both cases, as in other MSO deals, the structures include options, minority rights, preferences and potential contractual returns, but they are not equivalent to cash in the bank. Even a contractual put right depends on the counterparty's ability to finance the repurchase.
The Next Test Is Commercial And Cash-Based
The positive argument is straightforward: BrainsWay is not buying these options from weakness. In the first quarter, revenue grew 35%, gross margin held at 75%, the company shipped 117 Deep TMS systems, and management kept its 2026 revenue guidance at $66 million to $68 million. If the existing business continues to generate profit and positive cash flow, the company can afford to allocate part of its cash to assets that broaden patient, clinic and at-home treatment access.
The yellow flag is that these investments are not yet disclosed as a separate operating contribution. They are recorded as financial assets, some of them in private assets measured at Level 3 fair value, and the disclosure still does not show how much revenue, orders, system utilization or gross profit they already add to BrainsWay. This is not yet a proven growth story. It is a story about buying growth paths.
The near-term test has to be both cash-based and commercial. It is cash-based because one quarter already showed how private investments can more than absorb the cash generated by the core business. It is commercial because Neurolief's next stage requires revenue, and the MSO investments need to show that they increase access, utilization or demand for Deep TMS systems rather than only create exposure to private healthcare assets.
Short Conclusion
BrainsWay's private investments are not a balance-sheet problem right now, but they are already a material capital-allocation test. The company still has a relatively large cash balance, yet the first quarter shows that the new strategic path can consume cash faster than quarterly profit produces it. The read improves if Neurolief moves from regulatory approval to revenue that triggers the next stage, and if the MSO investments start to show up through RPO, system utilization, gross margin or cash flow. It weakens if acquisitions continue to increase private financial assets without operating proof, because excess cash would gradually become bridge funding for options that have not yet matured.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.